Dataset from A Randomized Phase 2, Double-blind, Placebo-controlled, Treat-to-Target, Parallel-group, 3-arm, Multicenter Study to Assess the Efficacy and Safety of Canagliflozin as Add-on Therapy to Insulin in the Treatment of Subjects With Type 1 Diabetes Mellitus
收藏NIAID Data Ecosystem2026-05-02 收录
下载链接：
https://doi.org/10.25934/PR00010130
下载链接
链接失效反馈官方服务：
资源简介：
The purpose of this study is to assess the effects of administration of canagliflozin 100 mg
and 300 mg, compared with placebo as an addition to insulin therapy for the treatment of Type
1 Diabetes Mellitus (T1DM).
创建时间：
2025-02-10
